Document:

Exhibit 10.1

 

THIRD AMENDMENT TO CREDIT AGREEMENT

 

This Third Amendment
to Credit Agreement (this “Amendment”) is made as of November 6, 2020 by and among Accolade, Inc. (“Borrower”),
MD Insider, Inc., the financial institutions signatory hereto (the “Lenders”) and Comerica Bank, as agent for the Lenders
(in such capacity, “Agent”).

 

RECITALS

 

A.                
Borrower, Agent and Lenders entered into that certain Credit Agreement, dated as of July 19, 2019 (as amended or otherwise
modified from time to time, the “Credit Agreement”).

 

B.                 Borrower has requested that Agent and the Lenders make certain amendments to the Credit Agreement, all as set forth herein
and Agent and the Lenders are willing to do so, but only on the terms and conditions set forth in this Amendment.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained and other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, Borrower, Agent and the Lenders agree as follows:

 

		1.	The following definitions in Section 1.1 of the Credit Agreement are amended and restated as follows:

 

“Revolving Credit Aggregate
Commitment” shall mean Eighty Million Dollars ($80,000,000.00), subject to increases pursuant to Section 2.12 hereof up to
the Revolving Credit Optional Increase Amount, and subject to reduction or termination under Section 2.11 or 9.2 hereof.

 

“Revolving Credit Optional
Increase Amount” shall mean an amount equal to $0.

 

		2.	The following is added as new subsection (m) to Section 8.4 of the Credit Agreement:

 

“(m) sales or transfers
of any of its Equity Interests pursuant to any follow-on public offering on the Nasdaq Global Select Market, as long as such sales
or transfers do not result in a Change of Control.”

 

		3.	Annex II attached to the Credit Agreement is amended, restated and replaced by Annex II to this
Amendment.

 

		4.	The Revolving Credit Aggregate Commitment shall be increased concurrently with this Amendment pursuant
to the exercise by the Borrower of its rights under Section 2.12 of the Credit Agreement (“Revolving Credit Aggregate Commitment
Increase”). The parties hereto acknowledge and agree that after giving effect to the this Amendment, (a) the definitions
of Revolving Credit Aggregate Commitment and Revolving Credit Optional Increase Amount shall be as defined in Section 1 above,
and (b) each Revolving Credit Lender shall (i) have Revolving Credit Percentages equal to the applicable percentages set forth
in new Annex II attached hereto, which shall amend, restate and replace Annex II in the Credit Agreement as in effect immediately
prior to the Third Amendment Effective Date, and (ii) hold Revolving Credit Advances outstanding on the Third Amendment Effective
Date in their respective Revolving Credit Percentages. To facilitate the foregoing, each Lender which as a result of the adjustments
of Revolving Credit Percentages evidenced by Annex II hereto is to hold a greater principal amount of Revolving Credit Advances
outstanding than such Lender had outstanding immediately prior to the Third Amendment Effective Date, shall deliver to the Agent
immediately available funds to cover its Revolving Credit Percentage
of any outstanding Revolving Credit Advances (and the Agent shall, to the extent of the funds so received, disburse funds to each
Lender which, as a result of the adjustment of the Revolving Credit Percentages, is to have a lesser principal amount of the Revolving
Credit Advances outstanding than such Lender had prior to the Third Amendment Effective Date); provided, however that any interest
and fees accrued to the Third Amendment Effective Date shall be distributed to the Lenders in accordance with their respective
Revolving Credit Percentages prior to the Third Amendment Effective Date.

 

    1 

     

    

 

		5.	This Amendment shall become effective (according to the terms hereof) on the date (the “Third
Amendment Effective Date”) that the following conditions have been fully satisfied by Borrower:

 

		(a)	Agent shall have received via facsimile or PDF (followed by the reasonably prompt delivery of original
signatures after the Third Amendment Effective Date) counterpart originals of this Amendment, in each case duly executed and delivered
by Agent, Borrower and the Lenders.

 

		(b)	Agent shall have received replacement Revolving Credit Notes for each Revolving Credit Lender,
duly executed and delivered by Borrower, in form reasonably satisfactory to Agent.

 

		(c)	Agent shall have received payment of all fees and out of pocket expenses incurred in connection
with this Amendment (including, without limitation, legal fees, and the fee set forth in Section 6 below).

 

		(d)	The conditions set forth in Section 2.12 of the Credit Agreement shall be satisfied by Borrower
or shall have been waived by Agent and the Lenders.

 

		6.	In consideration of this Amendment, Borrower shall pay to Agent, an upfront fee of $40,000 in respect
of the Revolving Credit Aggregate Commitment Increase, to be distributed by the Agent to the Lenders (including Comerica Bank)
who have approved, executed and delivered a commitment increase as part of this Amendment, payable on their respective Percentages
of the aggregate increase in such Lender’s Revolving Credit Commitment Amount pursuant to this Amendment, which fee shall
be earned, due and payable on the Third Amendment Effective Date.

 

		7.	Borrower hereby certifies to the Agent and the Lenders as of the Third Amendment Effective
                                                                                                      Date that (a) execution and delivery of this Amendment and the performance by each of the Credit Parties of its obligations
                                                                                                      under the Credit Agreement as amended hereby (herein, as so amended, the “Amended Credit Agreement”) are within
                                                                                                      such undersigned’s powers, have been duly authorized, are not in contravention of law or the terms of its articles of
                                                                                                      incorporation or bylaws or other organic documents of the parties thereto, as applicable, and except as have been previously
                                                                                                      obtained do not require the consent or approval, material to the amendments contemplated in this Amendment, of any
                                                                                                      governmental body, agency or authority, and the Amended Credit Agreement will constitute the valid and binding obligations of
                                                                                                      such undersigned parties enforceable in accordance with its terms, except as enforcement thereof may be limited by applicable
                                                                                                      bankruptcy, reorganization, insolvency, moratorium or similar laws affecting the enforcement of creditors’ rights
                                                                                                      generally and by general principles of equity (whether enforcement is sought in a proceeding in equity or at law), (b) the
                                                                                                      representations and warranties set forth in Article 6 of the Amended Credit Agreement are true and correct in all material
                                                                                                      respects on and as of the Third Amendment Effective Date (except to the extent such representations specifically relate to an
                                                                                                      earlier date, in which case such representations and warranties are true and correct
in all material respects as of such earlier date), (c) there have been no changes to any Credit Party’s constitutional documents
since August 21, 2020, and (d) on and as of the Third Amendment Effective Date, after giving effect to this Amendment, no Default
or Event of Default shall have occurred and be continuing.

 

    2 

     

    

 

		8.	Except as specifically set forth above, this Amendment shall not be deemed to amend or alter in
any respect the terms and conditions of the Credit Agreement (including without limitation all conditions and requirements for
Advances and any financial covenants), any of the Notes issued thereunder or any of the other Loan Documents. Nor shall this Amendment
constitute a waiver or release by the Agent or the Lenders of any right, remedy, Default or Event of Default under or a consent
to any transaction not meeting the terms and conditions of the Credit Agreement, any of the Notes issued thereunder or any of the
other Loan Documents. Furthermore, this Amendment shall not affect in any manner whatsoever any rights or remedies of the Lenders
with respect to any other non-compliance by Borrower with the Credit Agreement or the other Loan Documents, whether in the nature
of a Default or Event of Default, and whether now in existence or subsequently arising, and shall not apply to any other transaction.

 

		9.	MD Insider, Inc., party to that certain Guaranty, dated as of September 17, 2019 (the “Guaranty”)
hereby ratifies and confirms its obligations under the Amended Credit Agreement and the applicable Guaranty, and agrees that the
Guaranty remains in full force and effect after giving effect to the effectiveness of this Amendment, subject to no setoff, defense
or counterclaim. MD Insider, Inc. confirms that this reaffirmation is not required by the terms of the Guaranty and need not be
obtained in connection with any prior or future amendments or extensions of additional credit to Borrower.

 

		10.	Borrower and each other Credit Party hereby acknowledges and agrees that this Amendment and the
amendments contained herein do not constitute any course of dealing or other basis for altering any obligation of Borrower, any
other Credit Party, or any other party or any right, privilege or remedy of the Lenders under the Credit Agreement, any other Loan
Document, any other agreement or document, or any contract or instrument.

 

		11.	Except as specifically defined to the contrary herein, capitalized terms used in this Amendment
shall have the meanings set forth in the Credit Agreement.

 

		12.	This Amendment is a Loan Document.

 

		13.	This Amendment may be executed in counterparts in accordance with Section 13.9 of the Credit Agreement.

 

		14.	AS FURTHER CONSIDERATION FOR THE AGREEMENTS AND UNDERSTANDINGS HEREIN, EACH OF THE CREDIT PARTIES
HEREBY RELEASES AGENT, EACH LENDER, AND EACH OF THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, ATTORNEYS, AFFILIATES,
SUBSIDIARIES, SUCCESSORS AND ASSIGNS FROM ANY LIABILITY, CLAIM, RIGHT OR CAUSE OF ACTION WHICH NOW EXISTS, OR HEREAFTER ARISES,
WHETHER KNOWN OR UNKNOWN, ARISING FROM OR IN ANY WAY RELATED TO FACTS IN EXISTENCE AS OF THE DATE HEREOF. BY WAY OF EXAMPLE AND
NOT LIMITATION, THE FOREGOING INCLUDES ANY CLAIMS IN ANY WAY RELATED TO ACTIONS TAKEN OR OMITTED TO BE TAKEN BY AGENT OR ANY LENDER
UNDER THE LOAN DOCUMENTS, THE BUSINESS RELATIONSHIP WITH AGENT AND/OR
ANY LENDER AND ALL OTHER OBLIGATIONS OF ANY NATURE OR UNDERSTANDINGS (ACTUAL OR ALLEGED), ANY BANKING RELATIONSHIPS THAT ANY CREDIT
PARTY HAS OR MAY HAVE HAD WITH AGENT OR ANY LENDER AT ANY TIME AND FOR ANY REASON.

 

    3 

     

    

 

It is understood by each of the
Credit Parties and it is each Credit Party’s intention that the release set forth in the preceding paragraph (the “Release
Paragraph”) shall be effective as a full and final accord and satisfactory release of each and every matter specifically
referred to in the Release Paragraph. In furtherance of this intention, each Credit Party acknowledges that it is familiar with,
and upon advice of counsel, does hereby waive, any and all rights they may have or acquired under California Civil Code Section
1542, which reads as follows:

 

“A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER
FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT
WITH THE DEBTOR OR RELEASED PARTY.”

 

		15.	This Amendment shall be construed in accordance with and governed by the laws of the State of California.

 

    4 

     

    

 

WITNESS the due execution hereof as of the day and year first
above written.

 

	COMERICA BANK,
	as Administrative Agent and a Lender
	 
	By:	/s/ Walter Weston	 

	 	Walter Weston
	Its:	Senior Vice
                                         President

 

[Signature Page to Third Amendment to Credit
Agreement (17006066)]

 

    

     

    

 

	WESTERN ALLIANCE BANK,

    as Lender
	 
	By:	/s/ Whitley Mayberry	 
	Its:	Relationship Manager	 

 

[Signature Page to Third Amendment to Credit
Agreement (17006066)]

 

     

     

    

 

ACCOLADE, INC.,

as Borrower

 

	By:	/s/ Stephen H. Barnes	 
	Its:	C.F.O.	 

 

MD INSIDER, INC.,

 

	By:	/s/ Stephen H. Barnes	 
	Its:	President	 

 

[Signature Page to Third Amendment to Credit
Agreement (17006066)]

 

     

     

    

 

Annex II

 

Percentages and Allocations

 

Revolving Credit Facility

 

	 	 	REVOLVING	 	 	REVOLVING	 	 	 	 	 	 	 
	 	 	CREDIT	 	 	CREDIT	 	 	WEIGHTED	 	 	TOTAL	 
	LENDERS	 	PERCENTAGE	 	 	ALLOCATIONS	 	 	PERCENTAGE	 	 	ALLOCATIONS	 
	Comerica
    Bank	 	 	50	%	 	$	40,000,000.00	 	 	 	50	%	 	$	40,000,000.00	 
	Western
    Alliance Bank	 	 	50	%	 	$	40,000,000.00	 	 	 	50	%	 	$	40,000,000.00	 
	TOTALS	 	 	100	%	 	$	80,000,000.00	 	 	 	100	%	 	$	80,000,000.00	 

 

[Signature Page to Third Amendment to Credit Agreement
(17006066)]fixx-ex41_377.htm

 

Exhibit 4.1 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 28, 2017, by and among Homology Medicines, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (each, an “Investor,” and together with any subsequent investors, or transferees, who become parties hereto as “Investors” in accordance with the terms hereof, the “Investors”), and, solely for purposes of Section 2 (other than Subsections 2.1 and 2.10), Subsection 4.1 and Section 6 (other than Subsection 6.6), California Institute of Technology (“Caltech”). 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) possess registration rights, information rights, rights of first offer, and other rights pursuant to an Investors’ Rights Agreement, dated as of December 22, 2015, between the Company and such Investors (as amended, the “Prior Agreement”); 

WHEREAS, the Company and the Existing Investors desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 

WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the Investors are entering into a Series B Preferred Stock Purchase Agreement (as the same may be amended and/or restated from time to time, the “Purchase Agreement”), pursuant to which such Investors have agreed to purchase shares of Series B Preferred Stock (as defined below); 

WHEREAS, the Company and Caltech are parties to a License Agreement, dated as of September 14, 2016 (as amended, the “Caltech Agreement”), pursuant to which the Company issued to Caltech 533,695 shares of Common Stock and the Company agreed to grant certain registration and participation rights; and 

NOW, THEREFORE, the Company and the Existing Investors hereby agree that the Prior Agreement is amended and restated in its entirety as set forth herein, and all of the parties hereto further agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. 

1.2 “Caltech Registrable Securities” means (i) the 533,695 shares of Common Stock held by Caltech on the date hereof, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of such shares. 

1.3 “Common Stock” means shares of the Company’s common stock, $0.0001 par value per share. 

1.4 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or 

 

 

alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.6 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.7 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.8 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10 “Founders” means Saswati Chatterjee and Laura Smith. 

1.11 “GAAP” means generally accepted accounting principles in the United States. 

1.12 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act. 

1.16 “Key Employee” means any executive-level employee (including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.17 “Major Investor” means (i) any Investor that, individually or together with such Investor’s Affiliates, holds at least 7,000,000 shares of Registrable Securities after the Closing under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and (ii) for purposes of Section 4.1 only, Caltech for so long as they continue to hold all of the Caltech Registrable Securities. 

1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

2

 

1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity. 

1.20 “Preferred Director” means any director of the Company that the holders of record of the Preferred Stock, exclusively and voting together as a single class, are entitled to elect pursuant to the Restated Certificate. 

1.21 “Preferred Stock” means, collectively, the Series A Preferred Stock and the Series B Preferred Stock. 

1.22 “Qualified IPO” means an IPO in which the Company sells shares of its Common Stock with gross proceeds to the Company of at least $50,000,000 and the shares of Common Stock are listed for trading on the New York Stock Exchange or the NASDAQ National Market. 

1.23 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) the Caltech Registrable Securities, provided, however, that such Caltech Registrable Securities shall not be deemed Registrable Securities and Caltech shall not be deemed a Holder for the purposes of Subsections 2.1, 2.10, 3.1, 3.2 and 6.6; and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.24 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.25 “Requisite Investors” means the holders of shares of Preferred Stock representing at least seventy-one and one-half percent (71.5%) of the voting power of the outstanding shares of Preferred Stock. 

1.26 “Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time. 

1.27 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.28 “SEC” means the Securities and Exchange Commission. 

1.29 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.30 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.31 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.32 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.33 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, $0.0001 par value per share. 

1.34 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, $0.0001 par value per share. 

3

 

1.35 “Voting Agreement” means the Amended and Restated Voting Agreement of even date herewith by and among the Company, the Investors and the Key Holders, as amended and/or restated from time to time. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If (i) at any time after the fourth (4th) anniversary of the date of this Agreement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, that the Company file a Form S-1 registration statement with respect to at least twenty percent (20%) of the Registrable Securities then outstanding and having an anticipated aggregate offering price, net of Selling Expenses, which would exceed $20 million, or (ii) at any time or from time to time after one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of Registrable Securities that the Company file a Form S-1 registration statement with respect to Registrable Securities having an expected aggregate offering price, net of Selling Expenses, which would exceed $5,000,000, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from a Holder or Holders of Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holder or Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within thirty (30) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred (100) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred (100) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company 

4

 

shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) in any twelve (12) month period. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of 

5

 

Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty-five percent (25%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 

(f) use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

6

 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $35,000 per registration, of one counsel for the selling Holders selected by the Holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities included in such registration (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each 

7

 

such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, 

8

 

damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(d), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement. 

2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

9

 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241 or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, any securities of the Company purchased in the Company’s IPO, any securities of the Company purchased in open market transactions, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, AS AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

10

 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; and 

(b) the third anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. For so long as an aggregate of at least 7,000,000 shares of Registrable Securities remain outstanding (subject to adjustment for stock splits, dividends and the like with respect to the Preferred Stock), the Company shall deliver to each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company: 

(a) as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(e)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of recognized standing selected by the Board of Directors of the Company (or the Audit Committee thereof); 

(b) as soon as practicable, but in any event within thirty (30) days after the end of each fiscal year of the Company, a statement showing (i) all debt holders and (ii) the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

11

 

(c) as soon as practicable, but in any event within thirty (30) days after the end of each of the first three (3) quarters of each fiscal year of the Company, (i) unaudited statements of income and cash flows for such fiscal quarter, and a comparison between (x) the actual amounts as of and for such fiscal quarter and (y) the comparable amounts for the prior quarter and as included in the Budget for such quarter, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such quarter, and (ii) an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (a) be subject to normal year-end audit adjustments; and (b) not contain all notes thereto that may be required in accordance with GAAP); 

(d) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(f) with respect to the financial statements called for in Subsection 3.1(c) and Subsection 3.1(d), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (except as otherwise set forth in Subsection 3.1(c) and Subsection 3.1(d)) and fairly present the financial condition of the Company and its results of operation for the periods specified therein; and 

(g) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. For so long as an aggregate of at least 7,000,000 shares of Registrable Securities remain outstanding (subject to adjustment for stock splits, dividends and the like with respect to the Preferred Stock), the Company shall permit each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

12

 

3.3 Observer Rights. The Company shall invite a representative of (i) 5AM Ventures IV, L.P., (ii) Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, L.P., collectively (together, “Deerfield”) and (iii) TLS Beta Pte. Ltd. to attend all meetings of its Board of Directors and any committee of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such designating Investor or its representative is a competitor of the Company. 

3.4 Termination of Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. Any Major Investor (other than Caltech) shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates, provided that each such Affiliate agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement; provided that, Caltech may assign only its rights and obligations under this Subsection 4.1 in accordance with Subsection 6.1. 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such holder) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) At the expiration of such twenty (20) day period, the Company 

13

 

shall promptly notify any Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which the Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the holders of Preferred Stock in accordance with this Subsection 4.1. 

(d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; (iii) the issuance of shares of Preferred Stock to pursuant to the Purchase Agreement; and (iv) the issuance of up to 6,944,445 shares of Series B Preferred Stock to Novartis Institutes For Biomedical Research, Inc. or its affiliates (“Novartis”) in connection with the Company entering into a collaboration arrangement with Novartis. 

4.2 Directed IPO. If an IPO is undertaken, the Company will use its reasonable best efforts to cause the managing underwriter(s) of the IPO to designate a number of shares of the Common Stock to be offered in the IPO with an aggregate offering price of at least $10,000,000 (based on the price of the Common Stock in the IPO) for sale under a “directed shares program,” and shall instruct such underwriter(s) to allocate such directed shares program to Deerfield. The shares designated by the underwriter(s) for sale under a directed shares program are referred to herein as “directed shares.” Deerfield acknowledges that, despite the Company’s use of its reasonable best efforts, the underwriter(s) may determine in their sole discretion that it is not advisable to designate all such shares as directed shares in the IPO, in which case the number of directed shares may be reduced or no directed shares may be designated, as applicable. Deerfield also acknowledges that notwithstanding the terms of this Agreement, the sale of any directed shares to Deerfield pursuant to this Section 4.2 will only be made in compliance with NASD Rules 2110 and 2790 and federal, state, and local laws, rules, and regulations. In the event the sale of directed shares to Deerfield pursuant to this Section 4.2 is prohibited by federal, state, or local laws, rules or regulations (as determined by either (a) the Company or (b) Deerfield), the Company shall undertake its reasonable best efforts to approve and execute a private placement of Common Stock with an aggregate amount of proceeds equal to $10,000,000 (with a per share purchase price equal to the public offering price of the Common Stock in the IPO) with Deerfield concurrent with the closing of the IPO on such terms and conditions as are standard for such transactions and reasonably acceptable to each of the Company and Deerfield. 

4.3 Termination. The covenants set forth in Subsection 4.1 and Subsection 4.2 shall terminate and be of no further force or effect upon the earliest of (i) immediately before the consummation of the IPO (provided in the case of Subsection 4.2, that the Company complies with such Subsection in connection with such IPO), (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event. 

5. Additional Covenants. 

5.1 Insurance. The Company shall obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers, Directors and Officers liability insurance, with a limit of liability not less than three million 

14

 

dollars ($3,000,000) in an amount and on terms and conditions satisfactory to the Board of Directors, and will cause such insurance policy to be maintained until such time as the Board of Directors determines that such insurance should be discontinued and shall not be cancelable by the Company without the prior approval by the Board of Directors. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement in a form reasonably acceptable to the Board of Directors; and (ii) each Founder and Key Employee to enter into a one (1) year nonsolicitation agreement, in a form reasonably acceptable to the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Board of Directors. 

5.3 Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Investor Director Approval. So long as the holders of Preferred Stock are entitled to elect a Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of at least two Preferred Directors: 

(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d) make any investment inconsistent with any investment policy approved by the Board of Directors; 

(e) incur any aggregate indebtedness that is not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; 

(g) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive officers; 

(h) change the principal business of the Company, enter new lines of business, or exit the current line of business; 

(i) sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or 

(j) enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $500,000. 

15

 

5.5 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the non-employee directors and observers for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an audit committee (the “Audit Committee”) and compensation committee (the “Compensation Committee”), each of which shall consist of three (3) non-management directors. The Audit Committee will have the authority to approve the Budget and all non-budgeted capital expenditures. The Compensation Committee will have the authority to approve all compensation plans, including the issuance of options, stock and other incentive compensation for employees earning more than $200,000 per year. Each non-employee director shall be entitled in such person’s discretion to be a member of any Board committee. Each committee of the Board of Directors shall have at least one Preferred Director as a member. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 

5.7 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement of even date herewith among the Investors and the Company), the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 

5.8 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

16

 

5.9 Right to Conduct Activities. The Company hereby agrees and acknowledges that certain of the Investors and certain of their respective Affiliates are professional venture capital and private equity investment funds (collectively, the “Funds”), and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as may be conducted in the future). The parties agree that no Fund or any Fund Affiliate investment fund or any of their Affiliates, or any of their or their Affiliates’ partners, officers or representatives which manage or advise any such investment funds shall be considered a competitor of the Company solely as a result of such investment, management or advisory activities for purposes of this Agreement and the Company agrees that, to the extent permitted under applicable law, neither the Funds nor their Affiliates shall be liable to the Company for any claim solely arising out of, or solely based upon, (i) the investment by a Fund or any of their Affiliates in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of a Fund or Fund Affiliate to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Funds from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.10 Tax Reporting. The Company will comply with any obligation imposed on the Company to make any filing (including any filing on Internal Revenue Service Form 5471) as a result of any interest that the Company holds in a non-U.S. Person or any activities that the Company conducts outside of the U.S. and shall include in such filing any information necessary to obviate (to the extent possible) any similar obligation to which any shareholder would otherwise be subject with respect to such interest or such activity. The Company shall promptly provide each Investor with a copy of any such filing. 

5.11 Restrictions on Publicity. Each Investor agrees not to discuss the Purchase Agreement (including the transactions contemplated thereunder), use the name or logo of the Company or its Affiliates, or refer to the Company or its Affiliates, directly or indirectly, in connection with the sale of the Preferred Stock, in any advertisement, press release, professional or trade publication, or in any other manner without the approval of the Board of Directors. 

5.12 Termination of Covenants. The covenants set forth in this Section 5, except for Subsections 5.6, through 5.9, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 20% of such Holder’s shares of Registrable Securities immediately prior to such assignment or transfer; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. Notwithstanding the foregoing, Caltech may not assign or otherwise transfer any of its rights under this Agreement without the prior written consent of the Company; provided, however, that Caltech may assign its rights under Subsection 4.1 (together with its obligations) to Osage University Partners after giving the Company prior written notice of such transfer or to any other entity approved in writing in advance by the Company, and such assignee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and 

17

 

conditions of this Agreement, including without limitation the provisions of Subsection 2.11, and any other agreements between the Company and its stockholders applicable to the securities purchased by such assignee. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to any conflicts of laws principles that could result in the application of laws of any other jurisdiction. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.5 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto (including any address designated to receive a copy of such communication, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Peter N. Handrinos, Latham & Watkins LLP, 200 Clarendon Street, Boston, Massachusetts 02116, facsimile no.: (617) 948-6001, electronic mail: peter.handrinos@lw.com. If any notice or other communication given or made pursuant to this Agreement is required to be given to a group of parties pursuant to the terms hereof, such notice shall be sent to the members of such group substantially simultaneously (and in any event with a 24 hour period). 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party; and provided further that the Company may update Schedule A hereto at any time to reflect any transfers of shares of the Company’s capital stock or parties to be added to this Agreement, effected in accordance with the terms hereof, and to correct any errors in the information set forth therein, without the consent of the other parties hereto. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

18

 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates (other than Affiliates of Caltech) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.10 Dispute Resolution. Any unresolved controversy or claim arising out of or relating to this Agreement, except as (i) otherwise provided in this Agreement, or (ii) any such controversies or claims arising out of the Company’s intellectual property rights for which a provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in Boston, Massachusetts, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses, and 

(c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the Delaware Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. Each party will bear its own costs in respect of any disputes arising under this Agreement. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or the Court of Chancery of the State of Delaware. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

6.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

19

 

6.12 Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

6.13 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.14 Caltech. Caltech hereby agrees that the rights granted to Caltech hereunder shall be deemed to fully satisfy the obligations of the Company under Sections 5.13 and 5.14 of the Caltech Agreement, and neither Section 5.13 nor Section 5.14 of the Caltech Agreement shall have any further force or effect. 

[Remainder of Page Intentionally Left Blank] 

 

 

20

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above. 

 

	
HOMOLOGY MEDICINES, INC.

	
 
	
 

	
By:
	
 
	
/s/ Arthur Tzianabos

	
Name:
	
 
	
Arthur Tzianabos, Ph.D.

	
Title:
	
 
	
President and Chief Executive Officer

 

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
5AM VENTURES IV, L.P.

	
 

	
by 5AM Partners IV, LLC

its General Partner

	
 
	
 

	
By:
	
 
	
/s/ Scott Rocklage

	
Name:
	
 
	
Scott Rocklage

	
Title:
	
 
	
Managing Member

 

	
 
	
 
	
 

	
5AM CO-INVESTORS IV, L.P.

	
 

	
by 5AM Partners IV, LLC

its General Partner

	
 
	
 

	
By:
	
 
	
/s/ Scott Rocklage

	
Name:
	
 
	
Scott Rocklage

	
Title:
	
 
	
Managing Member

 

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
ARCH VENTURE FUND VIII, L.P.

	
 

	
By: ARCH Venture Partners VIII, L.P., its General Partner

	
 

	
By: ARCH Venture Partners VIII, LLC, its General Partner

	
 
	
 

	
By:
	
 
	
/s/ Mark McDonnell 

	
Name:
	
 
	
Mark McDonnell

	
Title:
	
 
	
Managing Director

 

	
 
	
 
	
 

	
ARCH VENTURE FUND VIII OVERAGE, L.P.

	
 

	
By: ARCH Venture Partners VIII, LLC, its General Partner

	
 
	
 

	
By:
	
 
	
/s/ Mark McDonnell

	
Name:
	
 
	
Mark McDonnell

	
Title:
	
 
	
Managing Director

 

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
TLS BETA PTE. LTD.

	
 
	
 

	
By:
	
 
	
/s/ Khoo Shih

	
Name:
	
 
	
Khoo Shih

	
Title:
	
 
	
Authorized Signatory

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.

	
 

	
By: Deerfield Mgmt HIF, L.P., its General Partner

	
 

	
By: J.E. Flynn Capital HIF LLC, its General Partner

	
 
	
 

	
By:
	
 
	
/s/ David J. Clark

	
Name:
	
 
	
David J. Clark

	
Title:
	
 
	
Authorized Signatory

 

	
 
	
 
	
 

	
DEERFIELD PRIVATE DESIGN FUND III, L.P.

	
 

	
By: Deerfield Mgmt III, L.P., its General Partner

	
 

	
By: J.E. Flynn Capital III LLC, its General Partner

	
 
	
 

	
By:
	
 
	
/s/ David J. Clark

	
Name:
	
 
	
David J. Clark

	
Title:
	
 
	
Authorized Signatory

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
FIDELITY GROWTH COMPANY

COMMINGLED POOL

	
By:
	
 
	
Fidelity Management & Trust Co.

	
 
	
 

	
By:
	
 
	
/s/ Stacie M. Smith 

	
Name:
	
 
	
Stacie M. Smith

	
Title:
	
 
	
Authorized Signatory

 

	
FIDELITY MT. VERNON STREET TRUST:

FIDELITY SERIES GROWTH COMPANY FUND

	
 
	
 

	
By:
	
 
	
/s/ Stacie M. Smith 

	
Name:
	
 
	
Stacie M. Smith

	
Title:
	
 
	
Authorized Signatory

 

	
FIDELITY MT. VERNON STREET TRUST:

FIDELITY GROWTH COMPANY FUND

	
 
	
 

	
By:
	
 
	
/s/ Stacie M. Smith

	
Name:
	
 
	
Stacie M. Smith

	
Title:
	
 
	
Authorized Signatory

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
ROCK SPRINGS CAPITAL MASTER FUND LP

	
 
	
 

	
By:
	
 
	
Rock Springs General Partner LLC

	
 
	
 

	
By:
	
 
	
/s/ Kris Jenner

	
Name:
	
 
	
Kris Jenner

	
Title:
	
 
	
Managing Member

[Signature Page to Investors’ Rights Agreement] 

 

 

 

 

	
INVESTORS:

	
 

	
OSAGE UNIVERSITY PARTNERS II, L.P.

	
 
	
 

	
By:
	
 
	
Osage University GP II, LP, its general partner

	
By:
	
 
	
Osage Partners, LLC, its general partner

	
 
	
 

	
By:
	
 
	
/s/ William Harrington

	
Name:
	
 
	
William Harrington

	
Title:
	
 
	
Member

 

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
VIDA VENTURES, LLC

	
 
	
 

	
By:
	
 
	
VV Manager, LLC., its Managing Member

	
 
	
 

	
By:
	
 
	
/s/ Clive D. Bode

	
Name:
	
 
	
Clive D. Bode

	
Title:
	
 
	
Manager

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
ALEXANDRIA VENTURE INVESTMENTS, LLC,

	
a Delaware limited liability company

	
 
	
 

	
By:
	
 
	
Alexandria Real Estate Equities, Inc.,

	
a Maryland corporation, managing member

	
 
	
 

	
By:
	
 
	
/s/ Aaron Jacobson

	
Name:
	
 
	
Aaron Jacobson

	
Title:
	
 
	
VP – Corporate Counsel

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
NOVARTIS INSTITUTES FOR BIOMEDICAL

RESEARCH, INC.

	
 
	
 

	
By:
	
 
	
/s/ Scott A. Brown

	
Name:
	
 
	
Scott A. Brown

	
Title:
	
 
	
VP, General Counsel

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
VIVO PANDA FUND, L.P.

	
 
	
 

	
By:
	
 
	
Vivo Panda, LLC, its general partner

	
 
	
 

	
By:
	
 
	
/s/ Mahendra Shah

	
Name:
	
 
	
Mahendra Shah

	
Title:
	
 
	
Managing Member

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
HBM HEALTHCARE INVESTMENTS

(CAYMAN) LTD.

	
 
	
 

	
By:
	
 
	
/s/ Jean Marc LeSieur

	
Name:
	
 
	
Jean Marc LeSieur

	
Title:
	
 
	
Director

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
INVESTORS:

	
 

	
MAVERICK PRIVATE OPPORTUNITIES

FUND, L.P.

	
 

	
By: Maverick Capital Ventures, LLC, its General Partner

	
 

	
By: Maverick Capital Advisors, L.P., its Manager

	
 
	
 

	
By:
	
 
	
/s/ Ginessa A. Avila

	
Name:
	
 
	
Ginessa A. Avila

	
Title:
	
 
	
Authorized Representative

	
 

	
MAVERICK ADVISORS FUND, L.P.

	
 

	
By: Maverick Capital Ventures, LLC, its General Partner

	
 

	
By: Maverick Capital Advisors, L.P., its Manager

	
 
	
 

	
By:
	
 
	
/s/ Ginessa A. Avila

	
Name:
	
 
	
Ginessa A. Avila

	
Title:
	
 
	
Authorized Representative

[Signature Page to Investors’ Rights Agreement] 

 

 

 

	
For purposes of Section 6.14 and the rights and obligations referenced therein:

	
 

	
CALIFORNIA INSTITUTE OF TECHNOLOGY

(Caltech)

	
 
	
 

	
By:
	
 
	
/s/ Fred Farina

	
Name:
	
 
	
Fred Farina

	
Title:
	
 
	
Chief Innovation & Corporate Partnership Officer

[Signature Page to Investors’ Rights Agreement] 

 

 

SCHEDULE A 

Investors 

5AM Ventures IV, L.P. 

5AM Co-Investors IV, L.P. 

Address: 

2200 Sand Hill Road, Suite 110 

Menlo Park, CA 94025 

Alexandria Venture Investments, LLC 

Address: 

385 E. Colorado Blvd., Suite 299 

Pasadena, CA 91101 

ARCH Venture Fund VIII, L.P. 

ARCH Venture Fund VIII Overage, L.P. 

Address: 

c/o ARCH Venture Partners VIII, L.P. 

8755 W. Higgins Road, Suite 1025 

Chicago, IL 60631 

Attn: Mark McDonnell 

Phone: [***] 

Fax: [***] 

Email: [***] 

With a copy, which shall not constitute notice, to: 

Proskauer Rose LLP 

One International Place 

Boston, MA 02110 

Attn: [***] 

Phone: [***] 

Fax: [***] 

Email: [***] 

Deerfield Healthcare Innovations Fund, L.P. 

Deerfield Private Design Fund III, L.P. 

Address: 

Deerfield Management Company, L.P. 

780 Third Avenue, 37th Flr. 

New York, NY 10017 

Attention: Lawrence Atinsky 

Tel: [***]Fax: [***] 

With a copy, which shall not constitute notice, to: 

Goodwin Procter LLP 

100 Northern Ave. 

Boston, MA 02210 

Attn: [***]Phone: [***] 

 

 

Fidelity Growth Company Commingled Pool 

Address: 

Mag & Co. 

c/o Brown Brothers Harriman & Co. 

Attn: Corporate Actions /Vault 

140 Broadway 

New York, NY 10005 

Email: [***] 

Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund 

Address: 

State Street Bank & Trust 

PO Box 5756 

Boston, Massachusetts 02206 

Attn: WAVELENGTH + CO Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund 

Email: [***]Fax number: [***] 

Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund 

Address: 

BNY Mellon 

Attn: Stacey Wolfe 

525 William Penn Place Rm 0400 

Pittsburgh, PA 15259 

Email: [***] 

Fax number: [***] 

HBM Healthcare Investments (Cayman) Ltd. 

Address: 

Governors Square, Suite #4-212-2

23 Lime Tree Bay Avenue 

West Bay, Grand Cayman 

Cayman Islands 

Maverick Private Opportunities Fund, L.P. 

Maverick Advisors Fund, L.P. 

Address: 

Maverick Capital, Ltd. 

300 Crescent Court, 18th Floor 

Dallas, TX 75201 

Phone: [***]Fax: [***] 

Email: [***] 

Novartis Institutes For BioMedical Research, Inc. 

Address: 

Novartis Institutes for BioMedical Research, Inc. 

250 Massachusetts Avenue 

Cambridge, MA 02139 

Attn: General Counsel 

With a copy, which shall not constitute notice, to: 

 

 

Hogan Lovells US LLP 

4085 Campbell Avenue 

Suite 100 

Menlo Park, CA 94025 

Attn: [***] 

Phone: [***] 

Fax: [***] 

Email: [***] 

Osage University Partners II, L.P. 

Address: 

50 Monument Road, Suite 201 

Bala Cynwyd, PA 19004 

Attn: Beth Grafstrom 

Rock Springs Capital Master Fund LP 

Address: 

650 South Exeter Street 

Suite 1070 

Baltimore, Maryland 21202 

Attention: General Counsel 

Email: [***] 

TLS Beta Pte. Ltd. 

Address: 

Attn: Khoo Shih 

60B Orchard Road 

#06-18 Tower 2 

The Atrium@Orchard 

Singapore 238891 

Vida Ventures, LLC 

Address: 

Tarrant Management, LLC 

TPG Family Office 

Attn: Sherri Conn 

301 Commerce Street, Suite 3150 

 

 

Fort Worth, TX 76102 

[***]With a copy, which shall not constitute notice, to: 

Vida Ventures 

31 St James Avenue, Boston, MA 02116 

Attn: Arjun Goyal 

[***] 

VIVO PANDA FUND, L.P. 

Address: 

505 Hamilton Avenue, Suite 207 

Palo Alto, CA 94301 

Attn: Mahendra Shah 

 

 

 

 

HOMOLOGY MEDICINES, INC.

AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT & REGISTRATION RIGHTS WAIVER

November 6, 2020

This Amendment No. 1 to the Amended and Restated Investors’ Rights Agreement & Registration Rights Waiver (this “Amendment and Waiver”) is entered into as of November 6, 2020 by and among Homology Medicines, Inc., a Delaware corporation (the “Company”), and certain stockholders of the Company party to the Investors’ Rights Agreement (as defined below) (collectively, the “Holders”).  Capitalized terms used and not defined herein shall have the meaning set forth in the Investors’ Rights Agreement.

Whereas, the Company and the Holders previously entered into that certain Amended and Restated Investors’ Rights Agreement, dated as of July 28, 2017 (the “Investors’ Rights Agreement”).  

Whereas, Section 6.6 of the Investors’ Rights Agreement provides that the Investors’ Rights Agreement generally may be amended with the written consent of (i) the Company and (ii) the holders of at least seventy-one and one-half percent (71.5%) of the Registrable Securities outstanding (the “Required Holders”);

Whereas, the Holders whose signatures appear on the signature pages attached hereto constitute the Required Holders under the Investors’ Rights Agreement necessary to amend the Investors’ Rights Agreement;

Whereas, on March 12, 2020, the Company filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), a Registration Statement on Form S-3 (Reg. No. 333-237131) covering the offer, issuance and sale of its shares of common stock and other securities (as so filed and as amended and/or supplemented from time to time, and, together with any related registration statement filed pursuant to Rule 462(b) under the Securities Act, the “Registration Statement”);  

Whereas, the Holders may be entitled to certain rights related to the registration of Registrable Securities, as set forth in the Investors’ Rights Agreement, including without limitation, the registration rights set forth in Section 2.2 thereof (the “Registration Rights”); and

Whereas, the Holders whose signatures appear on the signature pages attached hereto constituted the Required Holders under the Investors’ Rights Agreement necessary to waive the Registration Rights and related notice rights with respect to the filing of the Registration Statement with the Commission;

Whereas, the undersigned Holders, for and on behalf of all Holders, desire to (i) amend the Investors’ Rights Agreement as set forth below and (ii) waive the Registration Rights as provided herein with respect to the Registration Statement and related notice rights as provided herein with respect to the filing of the Registration Statement with the Commission and any offering of securities thereunder.

Now, Therefore, in consideration of the foregoing, the undersigned Holders hereby agree with the Company as follows:

1.Waiver of Notice.

Effective immediately prior to the filing of the Registration Statement with the Commission, the undersigned Holders hereby waive, for and on behalf of all Holders, any and all rights to notice under the Investors’ Rights Agreement or otherwise with respect to the Registration Statement, including without limitation, any amendments and supplements thereto and combined registration statements therewith, and any offering of securities thereunder.  

US-DOCS\114529651.63

 

2.Waiver of Registration Rights.

Effective immediately prior to the filing of the Registration Statement with the Commission, the undersigned Holders hereby waive, for and on behalf of all Holders, the Registration Rights and all other related or similar rights under the Investors’ Rights Agreement with respect to the Registration Statement, including without limitation, any amendments and supplements thereto and combined registration statements therewith, and any offering of securities thereunder.

3.Amendments

(a)The definition of “Registrable Securities” in subsection 1.23 of Section 1 of the Investors’ Rights Agreement is hereby amended and restated in its entirety, effective as of the date of the IPO, to read as follows:  

“1.23 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) the Caltech Registrable Securities, provided, however, that such Caltech Registrable Securities shall not be deemed Registrable Securities and Caltech shall not be deemed a Holder for the purposes of Subsections 2.1, 2.10, 3.1, 3.2 and 6.6; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, (A) any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1 and (B) any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.”

(b)Section 2.13 of the Investors’ Rights Agreement is hereby amended and restated in its entirety, effective as of the date of the IPO, to read as follows:  

“2.13Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of:

 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; 

(b) the third anniversary of the IPO; 

(c) such time at which all shares held by such Holder can be sold in any three (3) month period without registration or volume limitations in compliance with Rule 144 or another similar exemption, and

(d)such time at which such Holder is not an affiliate (as defined under the Act) of the Company.”

(c)Section 2.10 of the Investors’ Rights Agreement is hereby amended and restated in its entirety, effective as of the date of the IPO, to read as follows:  

“2.10Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9.”

US-DOCS\114529651.63

 

(d)Section 3.5 of the Investors’ Rights Agreement is hereby amended and restated in its entirety, effective as of the date of the IPO, to read as follows:  

“3.5Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement or in connection with the Company’s attempt to amend or seek any waiver of the terms of this Agreement (including notice of the Company’s intention to file a registration statement or to seek any amendment of or waiver thereunder), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.”

4.Miscellaneous.

Each of the undersigned Holders understands and acknowledges that the Company will proceed with offerings of securities under the Registration Statement in reliance on this Amendment and Waiver and in connection therewith hereby represents and warrants to the Company that: (i) such Holder has the full right, power and authority to execute and deliver this Amendment and Waiver, (ii) such Holder has not sold, transferred or otherwise disposed of any Registrable Securities prior to the date hereof, other than as set forth on such Holder’s signature page hereto, and (iii) this Amendment and Waiver has been duly executed and delivered by such Holder and constitutes the legal, valid and binding obligation thereof.

Except as expressly set forth herein, no other terms or provisions of the Investors’ Rights Agreement are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. This Amendment and Waiver may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute the same Amendment and Waiver.  This Amendment and Waiver is being signed by each undersigned Holder with respect to all Registrable Securities held by the same, as a shareholder of the Company and for all other purposes.  This Amendment and Waiver is irrevocable and shall be effective with respect to each of the undersigned Holders and all affiliates, successors, heirs, personal representatives, and assigns of the undersigned Holders. This Amendment and Waiver shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to its principles of conflict of laws that would result in the application of the laws of any other jurisdiction.

[the next page is the signature page]

US-DOCS\114529651.63

 

In Witness Whereof, each undersigned Holder has executed this Amendment and Waiver as of the date first written above.

 

	
5AM VENTURES IV, L.P.

	
 
	
 
	
 

	
By: 5AM Partners IV, LLC,

	
its General Partner

	
 
	
 
	
 

	
By:
	
 
	
/s/ Scott Rocklage

	
Name:
	
 
	
Scott Rocklage

	
Title:
	
 
	
Managing Member

 

	
Registrable Securities Held at IPO:
	
5,176,357

	
 
	
 

	
Registrable Securities Sold:
	
1,138,711

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
4,037,646

 

	
5AM CO-INVESTORS IV, L.P.

	
 
	
 
	
 

	
By: 5AM Partners IV, LLC,

	
its General Partner

	
 
	
 
	
 

	
By:
	
 
	
/s/ Scott Rocklage

	
Name:
	
 
	
Scott Rocklage

	
Title:
	
 
	
Managing Member

	
 
	
 
	
 

	
 
	
 
	
 

 

	
Registrable Securities Held at IPO:
	
215,680

	
 
	
 

	
Registrable Securities Sold:
	
47,446

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
168,234

 

 

 

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

US-DOCS\114529651.6

 

In Witness Whereof, each undersigned Holder has executed this Amendment and Waiver as of the date first written above.

 

	
ARCH VENTURE FUND VIII, L.P.

	
 
	
 
	
 

	
By: ARCH Venture Partners VIII, L.P., its General Partner

	
 

	
By: ARCH Venture Partners VIII, LLC, its General Partner

	
 
	
 
	
 

	
 
	
 
	
 

	
By:
	
 
	
/s/ Mark McDonnell

	
Name:
	
 
	
Mark McDonnell

	
Title:
	
 
	
Managing Director

 

	
Registrable Securities Held at IPO:
	
4,871,868

	
 
	
 

	
Registrable Securities Distributed in Kind:
	
240,837

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
4,631,031

 

	
ARCH VENTURE FUND VIII OVERAGE, L.P.

	
 
	
 
	
 

	
By: ARCH Venture Partners VIII, LLC, its General Partner

	
 

	
 
	
 
	
 

	
By:
	
 
	
/s/ Mark McDonnell

	
Name:
	
 
	
Mark McDonnell

	
Title:
	
 
	
Managing Director

 

	
Registrable Securities Held at IPO:
	
1,196,827

	
 
	
 

	
Registrable Securities Distributed in Kind:
	
59,164

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
1,137,663

 

 

 

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

US-DOCS\114529651.6

 

In Witness Whereof, each undersigned Holder has executed this Amendment and Waiver as of the date first written above.

 

	
TLS BETA PTE. LTD.

	
 
	
 
	
 

	
 
	
 
	
 

	
By:
	
 
	
/s/ Fida Alsagoff

	
Name:
	
 
	
Fida Alsagoff

	
Title:
	
 
	
Authorized Signatory

 

	
Registrable Securities Held at IPO:
	
2,595,293

	
 
	
 

	
Registrable Securities Sold:
	
0

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
2,595,293

 

 

 

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

US-DOCS\114529651.6

 

In Witness Whereof, each undersigned Holder has executed this Amendment and Waiver as of the date first written above.

 

	
VIVO PANDA FUND, L.P.

	
 
	
 
	
 

	
By: Vivo Panda, LLC., its general partner

	
 
	
 
	
 

	
By:
	
 
	
/s/ Mahendra Shah

	
Name:
	
 
	
Mahendra Shah

	
Title:
	
 
	
Managing Member

 

	
Registrable Securities Held at IPO:
	
659,742

	
 
	
 

	
Registrable Securities Sold:
	
289,674

	
 
	
 

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
370,068

 

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

 

 

US-DOCS\114529651.6

 

In Witness Whereof, each undersigned Holder has executed this Amendment and Waiver as of the date first written above.

 

	
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

	
 
	
 
	
 

	
 
	
 
	
 

	
By:
	
 
	
/s/ Scott A. Brown

	
Name:
	
 
	
Scott A. Brown

	
Title:
	
 
	
VP CAO

 

	
Registrable Securities Held at IPO:
	
1,979,226

	
 
	
 

	
Registrable Securities Sold:
	
0

	
 
	
 

	
 
	
 

	
Total Registrable Securities
	
 

	
Held on Date Hereof:
	
1,979,226

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

 

US-DOCS\114529651.6

 

Acknowledged and Agreed:

HOMOLOGY MEDICINES, INC.

 

	
 
	
 
	
 

	
By:
	
 
	
/s/ W. Bradford Smith

	
Name:
	
 
	
W. Bradford Smith

	
Title:
	
 
	
Chief Financial Officer

 

[Homology Medicines, Inc. – Signature Page to Amendment and Waiver]

 

 

US-DOCS\114529651.6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]